Houston Methodist opens new cellular therapeutics center

new to hou

New facility will accelerate investigational treatments in cancer, heart disease, neurological disorders and more. Photo courtesy of Houston Methodist

Houston Methodist recently opened a new 5,000-square-foot lab that will focus on developing and producing lifesaving treatments through cell therapy, the hospital announced last week.

Named the Ann Kimball & John W. Johnson Center for Cellular Therapeutics after long-time supporters of the hospital, the lab is located in the Houston Methodist Outpatient Center in the Texas Medical Center. The space includes 1710 square feet of cleanroom space, a dedicated quality control laboratory, six production rooms, support spaces and more to help develop new cell therapies and investigational therapeutics.

The combination of the control laboratory and production rooms onsite are anticipated to help the hospital treat patients safely and more efficiently, according to the statement.

Work at the JCCT is slated to benefit medical research throughout Houston Methodist in the fields of cancer, cardiovascular, neurology, organ transplantation, orthopedics and gastroenterology treatment.

The new center is named for Ann Kimball and John W. Johnson, who contributed a gift that will go toward establishing the facility. Photo courtesy of Houston Methodist

According to a statement from the hospital, cell therapy is "one of the most promising treatment options available," with applications in treatment for cancer, heart disease, and neurological diseases like ALS, Alzheimer’s and Parkinson’s. The therapy requires that a patient is implanted with live cells provided by a donor or the patient themselves. These cells can help repair or rejuvenate damaged tissue or cells.

“Many diseases have limited or ineffective therapies, so there is a tremendous need and opportunity to bring transformative and restorative new treatments to patients through cell therapy,” distinguished neurologist Dr Stanley Appel, who will lead the center, said the statement. “Having a cellular therapy laboratory on-site at Houston Methodist has always been a part of our vision. The Johnson family’s generosity and support of this vision will give hope to countless patients battling neurodegenerative diseases and more.”

The Johnsons' gift also created a matching fund that supports cell therapy projects in all specialties at Houston Methodist. At press time, the fund had helped attract 51 donors, including 69-year-old Jack McClanahan, who suffers from ALS and was the first to donate to the center.

"I volunteered for this because I want a younger man or woman with children to have a chance – this is a devastating disease,” McClanahan said in the statement. “If there’s any hope to help others, I just want to be part of it.”

Houston Methodist also announced last month that it will break ground on a $650 million Cypress "smart" hospital this spring. The hospital is slated to incorporate artificial intelligence, big data, and Alexa- and Siri-like voice technology into its treatment plans and design.

iBiochips was awarded a $1.5 million grant in September to help develop a new technology that delivers data about the cell's genetic makeup and reports abnormalities. Getty Images

Houston-based biotech company aims to revolutionize cellular dissection technology

digital disease detective

Innovative Biochips, a Houston-based biotechnology company, is one step closer to commercializing technology that the company hopes will provide an opportunity for researchers to detect diseases earlier.

The company was founded three years ago by Dr. Lidong Qin, a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist. Qin says he wanted to engineer and manufacture devices that focus on revolutionizing single-cell isolation and genetic analysis.

Qin says it can be difficult to launch a biotech startup in Houston, since the industry requires hefty initial funds to open a facility, get patents and hire a team of researchers.

"In the Houston area, even though it looks like it's a lot of state money (grants) around, it's very limited, and that's been a challenge of ours," Qin says.

But with the help of a $1.5 million investment from a private investor, Qin was able to launch iBiochips in 2015, and shortly after opened his own lab on Kirby Drive.

Recently, iBiochips was awarded a $1.5 million grant in September from the National Institutes of Health's Small Business Technology Transfer program. The grant will further support the company's research and development of an automated yeast dissection chip, which is designed to perform a raw analysis of single cells and deliver data about the cell's genetic makeup and report abnormalities.

Prior to the phase two grant, iBiochips was also awarded NIH's phase one grant of $225,000 in September 2017 to develop a prototype for the company's flagship cell isolation product, the Smart Aliquotor.

The Smart Aliquotor is a single-cell isolation dissection platform that allows scientists to analyze larger amounts of cells at a much faster rate than traditional isolation methods, Qin says. He says the system is also more convenient for researchers to operate because traditional cell isolation techniques require a lot of human effort.

To isolate the cells with a Smart Aliquotor, a scientist would take a patient's blood sample and inject it into a single point in the device. The blood sample would then travel through microfluidic channels into the device's 60 to 100 isolated holes, Qin says.

"In three days, we can handle about one million cells," Qin says. "In a traditional approach, people can handle only one or two cells in three days. So that is how we came to the [idea of the] chip can help a scientist do 20 years of work in three days."

The Smart Aliquotor can then be examined with iBiochips' newly funded automated dissection chip, which Qin says has the potential to detect cancer or infectious diseases earlier than before.

"If you isolate a cell by itself — even in the very beginning stage when the aggressive cells are not as dominating yet — you can still see that [abnormality in the sample]," Qin says.

iBiochips' products are currently only being manufactured for research use at clinical labs, universities and pharmacies. However, with the recent grant award, Qin says the company's research team plans to spend the next three to five years preparing the products for worldwide commercialization.

Dr. Lidong Qin is a professor at the Houston Methodist Research Institute's department of nanomedicine. He launched iBiochips as an independent faculty startup that licensed technology from Houston Methodist.Courtesy of Lidong Qin

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston students develop cost-effective glove to treat Parkinson's symptoms

smart glove

Two Rice undergraduate engineering students have developed a non-invasive vibrotactile glove that aims to alleviate the symptoms of Parkinson’s disease through therapeutic vibrations.

Emmie Casey and Tomi Kuye developed the project with support from the Oshman Engineering Design Kitchen (OEDK) and guidance from its director, Maria Oden, and Rice lecturer Heather Bisesti, according to a news release from the university.

The team based the design on research from the Peter Tass Lab at Stanford University, which explored how randomized vibratory stimuli delivered to the fingertips could help rewire misfiring neurons in the brain—a key component of Parkinson’s disease.

Clinical trials from Stanford showed that coordinated reset stimulation from the vibrations helped patients regain motor control and reduced abnormal brain activity. The effects lasted even after users removed the vibrotactile gloves.

Casey and Kuye set out to replicate the breakthrough at a lower cost. Their prototype replaced the expensive motors used in previous designs with motors found in smartphones that create similar tiny vibrations. They then embedded the motors into each fingertip of a wireless glove.

“We wanted to take this breakthrough and make it accessible to people who would never be able to afford an expensive medical device,” Casey said in the release. “We set out to design a glove that delivers the same therapeutic vibrations but at a fraction of the cost.”

Rice’s design also targets the root of the neurological disruption and attempts to retrain the brain. An early prototype was given to a family friend who had an early onset of the disease. According to anecdotal data from Rice, after six months of regularly using the gloves, the user was able to walk unaided.

“We’re not claiming it’s a cure,” Kuye said in the release. “But if it can give people just a little more control, a little more freedom, that’s life-changing.”

Casey and Kuye are working to develop a commercial version of the glove priced at $250. They are taking preorders and hope to release 500 pairs of gloves this fall. They've also published an open-source instruction manual online for others who want to try to build their own glove at home. They have also formed a nonprofit and plan to use a sliding scale price model to help users manage the cost.

“This project exemplifies what we strive for at the OEDK — empowering students to translate cutting-edge research into real-world solutions,” Oden added in the release. “Emmie and Tomi have shown extraordinary initiative and empathy in developing a device that could bring meaningful relief to people living with Parkinson’s, no matter their resources.”

New Austin tower eclipses Houston landmark as Texas' tallest building

Tallest in Texas

Texas officially has a new tallest tower. The title moves from Houston, for the JPMorgan Chase Tower, to Austin, for Waterline at 98 Red River St. The new tower will contain mixed-use spaces including apartments, offices, a hotel, restaurants, and retail. It is scheduled to open in full in 2026.

Waterline held a "topping out" ceremony in August, when the final beam was added to the top of the tower. It now reaches 74 stories and 1,025 feet — just 23 feet taller than the JPMorgan Chase Tower.

Waterline is now the tallest building in Texas.Graphic courtesy of Lincoln Property Company

According to a press release, hundreds of construction workers and team project members attended the Waterline ceremony, and more than 4,750 people have worked on it since the project broke ground in 2022. An estimated 875 people were working onsite every day at the busiest time for construction.

The Waterline site is on a 3.3-acre campus with lots of views of Waller Creek and Lady Bird Lake. The building contains space for 352 luxury apartments, 700,000 square feet of offices, a hotel called 1 Hotel Austin with 251 rooms, and 24,000 square feet of retail stores and restaurants.

The only space that is open to new tenants already is the office space, with residential soon to follow. The hotel and residential units are expected to open in fall 2026.

A view from above, shot by drone.Photo courtesy of Lincoln Property Company and Kairoi Residential

“Seamlessly integrated with Waller Creek, Waterloo Greenway and the hike-and-bike trail around Lady Bird Lake, Waterline will quickly become a top downtown destination and activity center," said Lincoln executive vice president Seth Johnston in a press release. Project improvements will also make it far easier for people to access all of the public amenities in this area from Rainey Street, the new Austin Convention Center, and the rest of the Central Business District."

---

This article originally appeared on CultureMap.com.

Houston company awarded $2.5B NASA contract to support astronaut health and space missions

space health

Houston-based technology and energy solution company KBR has been awarded a $2.5 billion NASA contract to support astronaut health and reduce risks during spaceflight missions.

Under the terms of the Human Health and Performance Contract 2, KBR will provide support services for several programs, including the Human Research Program, International Space Station Program, Commercial Crew Program, Artemis campaign and others. This will include ensuring crew health, safety, and performance; occupational health services and risk mitigation research for future flights.

“This contract reinforces KBR’s leadership in human spaceflight operations and highlights our expertise in supporting NASA’s vision for space exploration,” Mark Kavanaugh, KBR president of defense, intel and space, said in a news release.

The five-year contract will begin Nov. 1 with possible extension option periods that could last through 2035. The total estimated value of the base period plus the optional periods is $3.6 billion, and the majority of the work will be done at NASA’s Johnson Space Center.

“We’re proud to support NASA’s critical work on long-duration space travel, including the Artemis missions, while contributing to solutions that will help humans live and thrive beyond Earth,” Kavanaugh adde in the news release.

Recently, KBR and Axiom Space completed three successful crewed underwater tests of the Axiom Extravehicular Mobility Unit (AxEMU) at NASA's Neutral Buoyancy Laboratory (NBL) at Johnson Space Center. The tests were part of an effort to help both companies work to support NASA's return to the Moon, according to a release.

KBR also landed at No. 3 in a list of Texas businesses on Time and Statista’s new ranking of the country’s best midsize companies.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME